Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of rapcabtagene autoleucel in adult patients with CLL/SLL, relapsed/refractory ALL, relapsed/refractory DLBCL, and first-line high-risk LBCL
2023-507062-34-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Aug 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 8
01
Overview
Phase 2, open-label trial of rapcabtagene autoleucel in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) (4 cohorts), sponsored by Novartis. Planned start Aug 2020; status: authorised.
02
Drugs
rapcabtagene autoleucel
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-507062-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507062-34-00.